Morgens Waterfall Vintiadis & CO Inc Editas Medicine, Inc. Transaction History

Morgens Waterfall Vintiadis & CO Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $223,200 - $491,700	-15,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $414,750 - $575,850	-15,000 Reduced 50.0%	15,000 $477,000
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $298,400 - $440,800	10,000 Added 50.0%	30,000 $995,000
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $316,200 - $480,200	20,000	20,000 $480,000

228

54.2M

412K

355K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Morgens Waterfall Vintiadis & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Morgens Waterfall Vintiadis & CO Inc with notifications on news.